Spyre Therapeutics Inc. (NASDAQ: SYRE)
$31.01
+2.2050 ( +7.66% ) 718.7K
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
Market Data
Open
$31.01
Previous close
$28.80
Volume
718.7K
Market cap
$1.57B
Day range
$28.81 - $31.13
52 week range
$10.42 - $47.97
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Apr 25, 2024 |
4 | Insider transactions | 1 | Apr 25, 2024 |
ars | Annual reports | 1 | Apr 02, 2024 |
def | Proxies and info statements | 19 | Apr 01, 2024 |
pre | Proxies and info statements | 20 | Mar 20, 2024 |
8-k | 8K-related | 18 | Mar 18, 2024 |
10-k/a | Quarterly Reports | 18 | Mar 01, 2024 |
8-k | 8K-related | 16 | Feb 29, 2024 |
10-k | Annual reports | 121 | Feb 29, 2024 |
4 | Insider transactions | 1 | Feb 20, 2024 |